#BEGIN_DRUGCARD DB01060

# AHFS_Codes:
08:12.16.08

# ATC_Codes:
J01CA04

# Absorption:
Rapidly absorbed after oral administration.

# Biotransformation:
Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins

# Brand_Mixtures:
Augmentin (amoxicillin + clavulanic acid)
Co-amoxiclav (amoxicillin + clavulanic acid)
Prevpac (amoxicillin + clarithromycin + lansoprazole)

# Brand_Names:
AMPC
Actimoxi
Amoclen
Amolin
Amopen
Amopenixin
Amoxi
Amoxi-Mast
Amoxibiotic
Amoxiden
Amoxil
Amoxivet
Anemolin
Aspenil
Biomox
Bristamox
Cemoxin
Clamoxyl
Delacillin
Dispermox
Efpenix
Flemoxin
Hiconcil
Histocillin
Ibiamox
Imacillin
Lamoxy
Metafarma capsules
Metifarma capsules
Moxacin
Moxal
Ospamox
Pamoxicillin
Piramox
Polymox
Robamox
Sawamox PM
Sumox
Tolodina
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox

# CAS_Registry_Number:
26787-78-0

# ChEBI_ID:
2676

# Chemical_Formula:
C16H19N3O5S

# Chemical_IUPAC_Name:
(2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2262886

# Description:
A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation. [PubChem]

# Dosage_Forms:
Capsule	Oral
Powder, for solution	Oral
Powder, for suspension	Oral
Suspension	Oral
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Penicillins

# Drug_Interactions:
Demeclocycline	Possible antagonism of action
Doxycycline	Possible antagonism of action
Ethinyl Estradiol	This anti-infectious agent could decrease the effect of the oral contraceptive
Mestranol	This anti-infectious agent could decrease the effect of the oral contraceptive
Methacycline	Possible antagonism of action
Methotrexate	The penicillin increases the effect and toxicity of methotrexate
Minocycline	Possible antagonism of action
Oxytetracycline	Possible antagonism of action
Rolitetracycline	Possible antagonism of action
Tetracycline	Possible antagonism of action

# Drug_Reference:
20065329	Drawz SM, Bonomo RA: Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010 Jan;23(1):160-201.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-6.1

# Experimental_LogP_Hydrophobicity:
0.87

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
3430 mg/L

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Amoxicillin

# HET_ID:
Not Available

# Half_Life:
61.3 minutes

# InChI_Identifier:
InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1

# InChI_Key:
InChIKey=LSQZJLSUYDQPKJ-NJBDSQKTSA-N

# Indication:
For the treatment of infections of the ear, nose, and throat, the genitourinary tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only b-lactamase-negative) strains of <i>Streptococcus</i> spp. (a- and b-hemolytic strains only), <i>S. pneumoniae</i>, <i>Staphylococcus</i> spp., <i>H. influenzae</i>, <i>E. coli</i>, <i>P. mirabilis</i>, or <i>E. faecalis</i>. Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral infections) due to <i>N. gonorrhoeae</i> (males and females).

# KEGG_Compound_ID:
C06827

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1060

# Mechanism_Of_Action:
Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.

# Melting_Point:
194 Â°C

# Molecular_Weight_Avg:
365.404

# Molecular_Weight_Mono:
365.104541423

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448406

# Pharmacology:
Amoxicillin is a moderate-spectrum antibiotic active against a wide range of Gram-positive, and a limited range of Gram-negative organisms. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other beta-lactam antibiotics. Amoxicillin is susceptible to degradation by &beta;-lactamase-producing bacteria, and so may be given with clavulanic acid to increase its susceptability. The incidence of &beta;-lactamase-producing resistant organisms, including <i>E. coli</i>, appears to be increasing. Amoxicillin is sometimes combined with clavulanic acid, a &beta;-lactamase inhibitor, to increase the spectrum of action against Gram-negative organisms, and to overcome bacterial antibiotic resistance mediated through &beta;-lactamase production.

# Predicted_LogP_Hydrophobicity:
0.75

# Predicted_LogS:
-2.6

# Predicted_Water_Solubility:
9.58e-01 g/l

# Primary_Accession_No:
DB01060

# Protein_Binding:
In blood serum, amoxicillin is approximately 20% protein-bound

# PubChem_Compound_ID:
33613

# PubChem_Substance_ID:
46507578

# RxList_Link:
http://www.rxlist.com/cgi/generic/amox.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00248

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Amoxicilina [INN-Spanish]
Amoxicillin Trihydrate
Amoxicillin anhydrous
Amoxicilline [INN-French]
Amoxicillinum [INN-Latin]
Amoxycillin
Amoxycillin Trihydrate
D-Amoxicillin
p-Hydroxyampicillin

# Synthesis_Reference:
Not Available

# Toxicity:
Serious toxicity is unlikely following large doses of amoxicillin. Acute ingestion of large doses of amoxicillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.

# Update_Date:
2013-02-19 16:46:03 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Amoxicillin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_1_ID:
6016

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12461003	Okamoto T, Yoshiyama H, Nakazawa T, Park ID, Chang MW, Yanai H, Okita K, Shirai M: A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother. 2002 Dec;50(6):849-56.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
BA000016

# Drug_Target_1_GenBank_ID_Protein:
18145626

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pbpA

# Drug_Target_1_Gene_Sequence:
>2040 bp
ATGACTGAAAGAAAAAGAGAGCATAAAGATAGAAAGCAGAATAAAAATTCACCTAAAAAT
CAATCGAAAGTAACAAAATTTTTGAAATGGTTCTTTATAGGGATTCTGCTTCTAGGGATA
ACTGCCGTAACAGTAGTTGGAATTTACGTTCTTTCTATTATACGTTCATCTCCAGAGTTA
GATGTTCAGGCAATTCAATCTCTAAATCAGCCATCCATTCTTTACGATGATCAGGGAAAC
TTTATGGATAATGTTATAACTCGTGAACAACGTTATGTAGTTAAATCTGAAGAGATACCT
GATAACTTAAAAAAGGCTTTTGTAGCTATTGAAGACGAAAGATTTTATGAGCATAAAGGA
ATAGACATTAAAAGAATTTTTGGGGTAATAGCTTCTAATATTAAAGGTAAACTTTCAGGA
AGTAATACAGTTCAAGGGGCTTCAACCATAACTCAGCAACTTATAAAAAATGCCGTACTT
ACTAATGAAGTTAGTTATGAAAGAAAAATTAAAGAAATGTACTTAGCTTTGGAATTAGAA
AAGCACCTTTCAAAAGATGAAATCCTTACTACGTATTTAAATACAATTCCTATGGGTGGA
TACCAATATGGGGTTAGCGCAGCTGCTCAAAGATTTTTTAGTAAGAATGTTTCAGATTTG
AATTTAGTTGAGTGCGCTTATTTAGGAGGACTTACTCAAGCACCAACTTCTTATGATGGT
CTTTCAGAAGCAAATAAAGAAAATCCAAGTAGATATTTAAATAGAACTAAATCTGTACTA
TTTAAAATGCATGAACTTGGATATATTTCAAGTGAACAATATAATGACGCAATAAATGAA
ATTGACACAAATGGTATAAAATTCACACCAAATAATAAATTAAGTAAAACTAACTTTGAG
TGGTTCACAAGACCAGCTATAACTCAAGTTAAACAAGACTTAATGGATAAATATAAATAT
ACACAAGAGGAAGTTGACAAACTTATAGCTAATGGTGGATTAAAAATCTATACTTCAATG
GATAGAAATCTTCAAAATAATGTTCAAAAAGTTTTAGATGATCCAAATAACTATAAAGCT
ATAACTAATAATCCTAATGAAAAAAATGAAGATGGTGTTTATAAATTACAAGCATCTGCC
ACAATAATAGACTATAAAACAGGCCATGTTAAGGCTTTAGTTGGAGGAAGAGGGGAACAA
CCTGCTATGTCTCACAATAGAGCTTATTATGATTTAAAATCTATAGGTTCTGCAACAAAA
CCATTAACAGTTTATGGTCCTGCTATTGATTTAGGACTTGGTGGCGCTGGCTCTGTAGTA
AATGATTCTCCATTAAGTAATAAAGAGTTATCTTCTACAGGATATAAAGATCAACCTAAG
AATGAATACAATAGTTATAGAGGCCCTTTAACTTTTAGAGAAGCAATTAAAATCTCTAGT
AACTTAGCAGCCATAAAAGTTGCTAATGAAGTAGGTGTTTCAAACTCTATAGCTTATGGA
GAAAAATTAGGTCTTGTTTATGGACCTCATTCTAGAGGTATTTCCACAACAGCCTTAGGT
CAATTCCAAAATGACCCTAATAATCCTGATGGAGGAAATACTTATACTCTAGCTTCAGCC
TTCGGTGTTTTTGGTAATAACGGTGTTAAAACAAATGCTAAATTATATACAAAGGTATTA
GATTCTCATGGAAATGTAATTCTTGATACAAGTACTCCAGAAGAAACTAAAATATTTAGT
CCTCAAGCGTCTTATATAGTTTATGATATGCTTAAGGATCAAGTAGAAAGTGGCTCTGCA
AAATCTGCTAAATTTGGTAATATTCCTGTGGCGGGTAAAACAGGAACTACTACTGGAGAT
AAAGACTATTTATTTGCAGGATTAACTCCATATTATTCTGCGGCTATTTGGATTGGATAT
GATAAGCCTAGAGAAATGAGAACTAGTAGTGGTACTGTTACCTCTCCTATTTTCGGAAAA
ATAATGGGCTTAGCTCATAAAGACTTACAGTACAAAGAGGTTGACAACCTAGTGGAATAA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
11792842	Shimizu T, Ohtani K, Hirakawa H, Ohshima K, Yamashita A, Shiba T, Ogasawara N, Hattori M, Kuhara S, Hayashi H: Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):996-1001. Epub 2002 Jan 15.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
633

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
75178

# Drug_Target_1_Name:
Penicillin-binding proteins 1A/1B

# Drug_Target_1_Number_of_Residues:
679

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding proteins 1A/1B
MTERKREHKDRKQNKNSPKNQSKVTKFLKWFFIGILLLGITAVTVVGIYVLSIIRSSPEL
DVQAIQSLNQPSILYDDQGNFMDNVITREQRYVVKSEEIPDNLKKAFVAIEDERFYEHKG
IDIKRIFGVIASNIKGKLSGSNTVQGASTITQQLIKNAVLTNEVSYERKIKEMYLALELE
KHLSKDEILTTYLNTIPMGGYQYGVSAAAQRFFSKNVSDLNLVECAYLGGLTQAPTSYDG
LSEANKENPSRYLNRTKSVLFKMHELGYISSEQYNDAINEIDTNGIKFTPNNKLSKTNFE
WFTRPAITQVKQDLMDKYKYTQEEVDKLIANGGLKIYTSMDRNLQNNVQKVLDDPNNYKA
ITNNPNEKNEDGVYKLQASATIIDYKTGHVKALVGGRGEQPAMSHNRAYYDLKSIGSATK
PLTVYGPAIDLGLGGAGSVVNDSPLSNKELSSTGYKDQPKNEYNSYRGPLTFREAIKISS
NLAAIKVANEVGVSNSIAYGEKLGLVYGPHSRGISTTALGQFQNDPNNPDGGNTYTLASA
FGVFGNNGVKTNAKLYTKVLDSHGNVILDTSTPEETKIFSPQASYIVYDMLKDQVESGSA
KSAKFGNIPVAGKTGTTTGDKDYLFAGLTPYYSAAIWIGYDKPREMRTSSGTVTSPIFGK
IMGLAHKDLQYKEVDNLVE

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q8XJ01

# Drug_Target_1_SwissProt_Name:
PBPA_CLOPE

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
9.09

# Drug_Target_1_Transmembrane_Regions:
30-52

#END_DRUGCARD DB01060
